Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 12;226(Suppl 1):S110-S116.
doi: 10.1093/infdis/jiac059.

A Systematic Review of European Clinical Practice Guidelines for Respiratory Syncytial Virus Prophylaxis

Rachel M Reeves  1 , Maarten van Wijhe  2 , Toni Lehtonen  3   4 , Luca Stona  5 , Anne C Teirlinck  6 , Liliana Vazquez Fernandez  7 , You Li  8 , Richard Osei-Yeboah  1 , Thea K Fischer  2   9 , Terho Heikkinen  4   10 , Michiel van Boven  6 , Håkon Bøås  11 , Daniele Donà  12 , Elisa Barbieri  12 , Harry Campbell  1 ; RESCEU Investigators
Collaborators, Affiliations

A Systematic Review of European Clinical Practice Guidelines for Respiratory Syncytial Virus Prophylaxis

Rachel M Reeves et al. J Infect Dis. .

Abstract

Background: Since the widespread adoption of palivizumab prophylaxis in Europe, there have been a number of clinical practice guidelines (CPGs) published for the prevention of respiratory syncytial virus (RSV) infection in children. The aim of this systematic review was to identify CPGs for the prevention of RSV infection across Europe.

Methods: We performed a systematic literature search and contacted European influenza and respiratory virus networks and public health institutions, to identify national CPGs for the prevention of RSV infection. The Reporting Items for practice Guidelines in Healthcare (RIGHT) Statement checklist was applied to extract data and review the quality of reporting.

Results: A total of 20 national CPGs were identified, all published between 2000 and 2018. The greatest discrepancy between guidelines was the recommendations for palivizumab prophylaxis for premature infants, with recommendations varying by gestational age. All guidelines recommended or considered the use of palivizumab in infants with bronchopulmonary dysplasia, 85% (n = 17) in children with congenital heart disease (CHD), and 60% (n = 12) in children with severe combined immunodeficiency.

Conclusions: We recommend that agencies publishing RSV prevention guidelines adopt the RIGHT reporting requirements when updating these guidelines to improve the presentation of the evidence-base for decisions.

Keywords: RSV guidelines Europe; palivizumab; prophylaxis.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. H. C. reports grants, personal fees, and nonfinancial support from World Health Organization; grants and personal fees from Sanofi; and grants from Bill and Melinda Gates Foundation, outside the submitted work. R. M. R. is supported by a grant from Innovative Medicines Initiative. T. L. reports support from the Finnish Institute for Health and Welfare and Turku University Hospital. Y. L. reports grants from the World Health Organization-Wellcome Trust. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Publication types

MeSH terms